In MS, the immune system has derailed, setting a cascade of processes in motion that ultimately results in damage to the body’s own cells and molecules.
Investigating the safety and feasibility of the vaccine will be a crucial step in the development of novel treatment strategies for MS. In order to perform this clinical trial, the researchers received support from the European Union’s Horizon 2020 research and innovation programme, enabling collaboration among several EU research institutes and companies.
H2020 Restore’s goal
This project is based on the major progress that has been made in the understanding and treatment of MS and focuses on the development of more selective immunomodulatory therapies with fewer side effects and with the potential for long-term disease remission. The overall goal of the ReSToRe project is to assess the safety and demonstrate first proof-of-concept of administering clinical-grade vitamin D3-treated tolDC loaded with myelin-derived peptides via different administration routes to treat a well-defined subpopulation of MS patients.Continue reading...
What is MS? Context of the problem
In young adults, multiple sclerosis (MS) is the main cause of non-traumatic neurological disability with no cure available to date. Around 500,000 people in Europe and 2.5 million people worldwide suffer from MS.Continue reading...
DC are a highly specialized population of white blood cells that are capable of orchestrating the immune responses. In their immature state, DC reside in the peripheral tissues, such as the skin, airways and intestine, where they function as the “sentinels” of the immune system, i.e. they patrol the body to capture antigens, including self-antigens, invading pathogens and certain malignant cells.Continue reading...
News & Events
The latest news & developments from the H2020 Restore project.
30th May 2021
The ReSToRe team supports World MS Day
Today is World MS Day. It is the day that individuals and organizations from all over the world unite to raise awareness for multiple sclerosis. By making more people understand what life with MS is like, more people will feel compelled to do something about it. With the entire international ReSToRe team, we are committed to find a solution for this devastating disease by bringing an antigen-specific tolerance-inducing dendritic cell (tolDC) therapy to treat MS patients to the clinic. Today, we have completed patient recruitment in both phase I clinical trials in Belgium and Spain. In total, 3 cohorts of 3 patients or 18 patients have received the treatment and we are finalizing the safety follow-up. We expect the first results of the safety studies of this innovative cell-based therapy by the end of the year. If this phase is successfully completed, a larger group of patients can be treated in phase II clinical trials. Only then, information about effectiveness of the treatment will be collected. These phase II studies are scheduled for 2022. Recruitment for these trials has not started yet. By connecting researchers, clinicians and patients, the ReSToRe consortium is helping to build a community that strives to beat MS.
11th September 2018
September 2018 H2020 ReSToRe researchers meet at the European Congress of Immunology
Professor Marieke Vanham, partner of the H2020 ReSToRe project and ECI congress president, hosts the 5th European Congress of Immunology (ECI) in Amsterdam from September 2-5, 2018. During the meeting, basic and clinical researchers can dive into immunology and discuss science. But there is more, ample exposure will be given to the research performed by H2020 ReSToRe collaborators. Eva Martinez-Caceres of the Catalan Institute of Health (Badalona, Spain) was invited to the ECI meeting to present her work on the development of a vitamin D3-treated tolDC vaccine for the treatment of MS. Others will present their research at the various poster sessions.
3rd September 2018
Professor Cools will represent ReSToRe at the International Society for Cellular Therapy in Firenze
Nathalie Cools of the University of Antwerp (Belgium) was invited to the International Society for Cellular Therapy in Firenze, Italy, to present the first safety and feasibility results of the ongoing clinical trial.
29th August 2018
Our Facebook page was launched
From now on, you can follow our work and activities on Facebook as well! Like and share…
This is a medical-scientific study, more specifically an open-label Phase I clinical trial, limited to Belgium and Spain in which about twenty patients per country will participate. Below you will find non-committal information about the study. Feel free to share and discuss this information with your neurologist.Read more...
Dit is een medisch-wetenschappelijk onderzoek, meer bepaald een open-label fase I klinische studie, beperkt tot België en Spanje waaraan in totaal een twintigtal patiënten zullen deelnemen. Hieronder vindt u, geheel vrijblijvend, meer informatie over de studie. Indien u dat wenst, kan u deze informatie ook delen en bespreken met uw neuroloog.Verder lezen...
Información del paciente
El estudio RESTORE está diseñado para personas que sufren esclerosis múltiple (EM). Se trata de un ensayo clínico Fase I que se realiza en 2 países: Bélgica y España. Está previsto que en cada uno de los países participen unos veinte pacientes. A continuación encontrará información sobre este ensayo.Leer más...
Informationen zum Patienten
Dies ist eine medizinisch-wissenschaftliche Studie, genauer gesagt eine offene klinische Phase-I-Studie, beschränkt auf Belgien und Spanien, an der insgesamt zwanzig Patienten teilnehmen werden. Nachfolgend finden Sie unverbindlich weitere Informationen zur Studie. Wenn Sie möchten, können Sie diese Informationen auch mit Ihrem Neurologen teilen und besprechen.Weiterlesen...
Information du patient
Une traduction sera disponible bientôt.